| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.884 | 0.003 | 0.981 | Factor X inhibitor | 0.888 0.003 DBMET01533 0.427 0.004 DBMET01534 0.981 0.002 DBMET01535 0.12 0.009 DBMET01536 0.116 0.009 DBMET01537 0.091 0.012 DBMET01538 0.07 0.015 DBMET01539 | DBMET01535 | |
| 0.682 | 0.005 | 0.949 | Anticoagulant | 0.711 0.005 DBMET01533 0.619 0.005 DBMET01534 0.949 0.003 DBMET01535 0.167 0.068 DBMET01536 0.189 0.057 DBMET01537 0.152 0.079 DBMET01538 0.325 0.024 DBMET01539 | DBMET01535 | |
| 0.669 | 0.002 | 0.669 | Factor Xa inhibitor | 0.617 0.002 DBMET01533 0.628 0.002 DBMET01534 0.149 0.008 DBMET01535 0.187 0.006 DBMET01536 0.15 0.008 DBMET01537 0.113 0.012 DBMET01538 0.217 0.005 DBMET01539 | ||
| 0.513 | 0.023 | 0.848 | Aryl hydrocarbon receptor agonist | 0.439 0.031 DBMET01533 0.446 0.03 DBMET01534 0.848 0.005 DBMET01536 0.794 0.005 DBMET01537 0.638 0.012 DBMET01538 0.25 0.079 DBMET01539 | DBMET01536 | |
| 0.413 | 0.07 | 0.652 | 5 Hydroxytryptamine release inhibitor | 0.448 0.052 DBMET01533 0.409 0.072 DBMET01534 0.652 0.006 DBMET01535 0.336 0.128 DBMET01536 0.368 0.1 DBMET01537 0.307 0.157 DBMET01538 | DBMET01535 | |
| 0.323 | 0.043 | 0.323 | Potassium channel (Voltage-sensitive) blocker | 0.239 0.073 DBMET01533 0.268 0.06 DBMET01535 | ||
| 0.315 | 0.045 | 0.351 | HERG channel blocker | 0.244 0.069 DBMET01533 0.351 0.037 DBMET01535 | DBMET01535 | |
| 0.292 | 0.049 | 0.292 | Potassium channel blocker | 0.204 0.09 DBMET01533 | ||
| 0.249 | 0.052 | 0.456 | Platelet aggregation inhibitor | 0.184 0.094 DBMET01533 0.415 0.017 DBMET01534 0.456 0.013 DBMET01535 | DBMET01535 | |
| 0.169 | 0.032 | 0.244 | Aurora-C kinase inhibitor | 0.18 0.027 DBMET01533 0.179 0.027 DBMET01534 0.228 0.013 DBMET01536 0.244 0.01 DBMET01537 0.199 0.02 DBMET01538 0.156 0.044 DBMET01539 | DBMET01537 | |
| 0.14 | 0.008 | 0.207 | Urokinase inhibitor | 0.145 0.008 DBMET01533 0.147 0.007 DBMET01534 0.207 0.004 DBMET01535 0.066 0.026 DBMET01536 0.074 0.023 DBMET01537 0.05 0.033 DBMET01538 | DBMET01535 | |
| 0.14 | 0.008 | 0.265 | Factor VIIa inhibitor | 0.142 0.008 DBMET01533 0.161 0.007 DBMET01534 0.265 0.004 DBMET01535 | DBMET01535 | |
| 0.207 | 0.077 | 0.374 | Pyruvate kinase inhibitor | 0.274 0.055 DBMET01533 0.184 0.091 DBMET01534 0.265 0.057 DBMET01535 0.23 0.067 DBMET01536 0.302 0.047 DBMET01537 0.374 0.026 DBMET01538 | DBMET01538 | |
| 0.216 | 0.09 | 0.724 | Platelet antagonist | 0.235 0.079 DBMET01533 0.344 0.04 DBMET01534 0.724 0.005 DBMET01535 | DBMET01535 | |
| 0.133 | 0.014 | 0.314 | Thrombin inhibitor | 0.136 0.013 DBMET01533 0.152 0.011 DBMET01534 0.314 0.004 DBMET01535 0.073 0.051 DBMET01539 | DBMET01535 | |
| 0.243 | 0.128 | 0.501 | Angiogenesis inhibitor | 0.207 0.161 DBMET01533 0.374 0.061 DBMET01534 0.439 0.042 DBMET01536 0.392 0.056 DBMET01537 0.412 0.05 DBMET01538 0.501 0.029 DBMET01539 | DBMET01539 | |
| 0.133 | 0.029 | 0.133 | Interleukin 2 antagonist | 0.133 0.03 DBMET01533 0.128 0.035 DBMET01534 0.128 0.034 DBMET01536 0.127 0.035 DBMET01537 0.11 0.064 DBMET01538 | ||
| 0.127 | 0.025 | 0.191 | Toll-Like receptor 3 antagonist | 0.097 0.056 DBMET01533 0.151 0.014 DBMET01534 0.191 0.007 DBMET01536 0.147 0.015 DBMET01537 0.132 0.022 DBMET01538 0.115 0.034 DBMET01539 | DBMET01536 | |
| 0.206 | 0.111 | 0.642 | Superoxide dismutase inhibitor | 0.228 0.091 DBMET01533 0.212 0.104 DBMET01534 0.384 0.03 DBMET01535 0.529 0.01 DBMET01536 0.582 0.008 DBMET01537 0.481 0.015 DBMET01538 0.642 0.005 DBMET01539 | DBMET01539 | |
| 0.105 | 0.015 | 0.513 | Trypsin inhibitor | 0.107 0.014 DBMET01533 0.111 0.013 DBMET01534 0.513 0.004 DBMET01535 | DBMET01535 | |
| 0.098 | 0.01 | 0.142 | Factor IXa inhibitor | 0.107 0.008 DBMET01533 0.097 0.01 DBMET01534 0.142 0.004 DBMET01535 0.054 0.033 DBMET01536 0.066 0.023 DBMET01537 0.05 0.037 DBMET01538 0.086 0.014 DBMET01539 | DBMET01535 | |
| 0.221 | 0.152 | 0.613 | Antithrombotic | 0.272 0.11 DBMET01533 0.613 0.015 DBMET01535 | DBMET01535 | |
| 0.085 | 0.022 | 0.175 | Plasminogen activator inhibitor | 0.092 0.019 DBMET01533 0.087 0.022 DBMET01534 0.175 0.005 DBMET01535 | DBMET01535 | |
| 0.125 | 0.065 | 0.216 | Protein-tyrosine kinase (PTK, not ETK, WZC) inhibitor | 0.121 0.068 DBMET01533 0.117 0.071 DBMET01534 0.216 0.024 DBMET01536 0.212 0.025 DBMET01537 0.148 0.049 DBMET01538 | DBMET01536 | |
| 0.079 | 0.019 | 0.182 | Kallikrein 1 inhibitor | 0.083 0.017 DBMET01533 0.079 0.018 DBMET01534 0.182 0.005 DBMET01535 | DBMET01535 | |
| 0.124 | 0.065 | 0.215 | Abl kinase inhibitor | 0.12 0.069 DBMET01533 0.117 0.071 DBMET01534 0.215 0.024 DBMET01536 0.21 0.025 DBMET01537 0.147 0.049 DBMET01538 | DBMET01536 | |
| 0.069 | 0.011 | 0.176 | Factor III inhibitor | 0.073 0.009 DBMET01533 0.07 0.01 DBMET01534 0.176 0.003 DBMET01535 | DBMET01535 | |
| 0.071 | 0.018 | 0.128 | Kallikrein inhibitor | 0.069 0.019 DBMET01533 0.09 0.012 DBMET01534 0.128 0.007 DBMET01535 | DBMET01535 | |
| 0.082 | 0.034 | 0.167 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.083 0.032 DBMET01533 0.167 0.003 DBMET01535 | DBMET01535 | |
| 0.212 | 0.166 | 0.212 | Ca(v)3.3 blocker | 0.203 0.185 DBMET01534 | ||
| 0.103 | 0.06 | 0.116 | Hedgehog signaling inhibitor | 0.104 0.058 DBMET01533 0.116 0.044 DBMET01534 0.089 0.087 DBMET01536 0.09 0.085 DBMET01537 | DBMET01534 | |
| 0.281 | 0.239 | 0.451 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.277 0.246 DBMET01533 0.328 0.177 DBMET01534 0.451 0.061 DBMET01535 0.365 0.135 DBMET01536 0.36 0.14 DBMET01537 | DBMET01535 | |
| 0.053 | 0.011 | 0.529 | Trypsin I inhibitor | 0.056 0.01 DBMET01533 0.042 0.016 DBMET01534 0.529 0.003 DBMET01535 | DBMET01535 | |
| 0.089 | 0.053 | 0.159 | Bcr-Abl kinase inhibitor | 0.095 0.046 DBMET01533 0.083 0.06 DBMET01534 0.145 0.018 DBMET01536 0.159 0.015 DBMET01537 0.076 0.069 DBMET01538 | DBMET01537 | |
| 0.157 | 0.124 | 0.18 | MAP kinase kinase 5 inhibitor | 0.18 0.062 DBMET01536 0.16 0.114 DBMET01537 0.163 0.105 DBMET01538 | DBMET01536 | |
| 0.045 | 0.014 | 0.061 | Plasma kallikrein inhibitor | 0.042 0.016 DBMET01533 0.061 0.009 DBMET01534 0.059 0.009 DBMET01535 | DBMET01534 | |
| 0.043 | 0.013 | 0.17 | Factor VII inhibitor | 0.056 0.011 DBMET01533 0.047 0.012 DBMET01534 0.17 0.004 DBMET01535 | DBMET01535 | |
| 0.036 | 0.009 | 0.049 | 5 Hydroxytryptamine 1F agonist | 0.037 0.009 DBMET01533 0.03 0.012 DBMET01534 0.048 0.005 DBMET01536 0.049 0.005 DBMET01537 0.027 0.016 DBMET01538 | DBMET01537 | |
| 0.073 | 0.051 | 0.191 | Nav1.8 sodium channel blocker | 0.191 0.009 DBMET01534 0.105 0.026 DBMET01536 0.078 0.045 DBMET01537 0.075 0.048 DBMET01538 | DBMET01534 | |
| 0.028 | 0.007 | 0.047 | Factor IX inhibitor | 0.029 0.006 DBMET01533 0.029 0.006 DBMET01534 0.047 0.004 DBMET01535 | DBMET01535 | |
| 0.038 | 0.017 | 0.075 | Calcium release-activated channel blocker | 0.034 0.021 DBMET01534 0.075 0.004 DBMET01536 0.044 0.013 DBMET01537 0.036 0.019 DBMET01538 | DBMET01536 | |
| 0.063 | 0.049 | 0.1 | Aryl hydrocarbon receptor antagonist | 0.066 0.043 DBMET01534 0.1 0.014 DBMET01536 0.091 0.018 DBMET01537 0.087 0.021 DBMET01538 | DBMET01536 | |
| 0.167 | 0.154 | 0.233 | Peptidyltransferase inhibitor | 0.217 0.079 DBMET01533 0.182 0.126 DBMET01534 0.22 0.076 DBMET01535 0.172 0.142 DBMET01536 0.233 0.064 DBMET01537 0.187 0.117 DBMET01538 | DBMET01537 | |
| 0.168 | 0.157 | 0.305 | Nitric-oxide synthase stimulant | 0.185 0.117 DBMET01533 0.184 0.119 DBMET01534 0.283 0.016 DBMET01536 0.305 0.01 DBMET01537 0.296 0.012 DBMET01538 0.194 0.099 DBMET01539 | DBMET01537 | |
| 0.046 | 0.035 | 0.481 | GP IIb/IIIa receptor antagonist | 0.053 0.031 DBMET01533 0.082 0.021 DBMET01534 0.481 0.004 DBMET01535 | DBMET01535 | |
| 0.075 | 0.067 | 0.144 | ALK inhibitor | 0.078 0.063 DBMET01534 0.144 0.021 DBMET01536 0.123 0.028 DBMET01537 0.108 0.037 DBMET01538 | DBMET01536 | |
| 0.018 | 0.014 | 0.021 | Complement factor D inhibitor | 0.021 0.008 DBMET01536 | DBMET01536 | |
| 0.116 | 0.113 | 0.179 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.126 0.099 DBMET01533 0.115 0.114 DBMET01534 0.161 0.065 DBMET01536 0.179 0.054 DBMET01537 0.16 0.066 DBMET01538 | DBMET01537 | |
| 0.119 | 0.116 | 0.449 | Sigma receptor agonist | 0.449 0.015 DBMET01535 | DBMET01535 | |
| 0.027 | 0.025 | 0.093 | Trypsin II inhibitor | 0.027 0.024 DBMET01534 0.093 0.004 DBMET01535 | DBMET01535 | |
| 0.118 | 0.12 | 0.124 | Death-associated protein kinase 1 inhibitor | 0.124 0.1 DBMET01536 0.119 0.115 DBMET01538 | DBMET01536 | |
| 0.032 | 0.035 | 0.287 | Tryptase inhibitor | 0.287 0.004 DBMET01535 | DBMET01535 | |
| 0.038 | 0.042 | 0.225 | Plasmin inhibitor | 0.043 0.036 DBMET01533 0.06 0.028 DBMET01534 0.225 0.005 DBMET01535 | DBMET01535 | |
| 0.074 | 0.08 | 0.122 | Proto-oncogene tyrosine-protein kinase Kit inhibitor | 0.078 0.075 DBMET01534 0.122 0.044 DBMET01536 | DBMET01536 | |
| 0.016 | 0.021 | 0.101 | Hexokinase stimulant | 0.101 0.004 DBMET01536 0.057 0.004 DBMET01537 0.035 0.007 DBMET01538 | DBMET01536 | |
| 0.069 | 0.078 | 0.094 | ErbB-3 antagonist | 0.094 0.046 DBMET01536 | DBMET01536 | |
| 0.082 | 0.091 | 0.151 | Insulin receptor antagonist | 0.151 0.027 DBMET01536 0.107 0.053 DBMET01537 | DBMET01536 | |
| 0.033 | 0.045 | 0.085 | Acid-sensing ion channel blocker | 0.085 0.004 DBMET01535 | DBMET01535 | |
| 0.014 | 0.027 | 0.026 | Complement factor 1 inhibitor | 0.026 0.004 DBMET01535 | DBMET01535 | |
| 0.021 | 0.036 | 0.029 | Complement factor 1r inhibitor | 0.029 0.012 DBMET01535 | DBMET01535 | |
| 0.057 | 0.072 | 0.133 | Rho-associated kinase inhibitor | 0.133 0.023 DBMET01536 0.105 0.032 DBMET01537 0.064 0.061 DBMET01538 | DBMET01536 | |
| 0.073 | 0.093 | 0.13 | Breast cancer-resistant protein inhibitor | 0.104 0.052 DBMET01536 0.12 0.039 DBMET01538 0.13 0.033 DBMET01539 | DBMET01539 | |
| 0.07 | 0.091 | 0.095 | Factor XII inhibitor | 0.095 0.043 DBMET01535 | DBMET01535 | |
| 0.14 | 0.164 | 0.176 | Growth factor agonist | 0.149 0.143 DBMET01534 0.17 0.102 DBMET01536 0.176 0.092 DBMET01537 0.154 0.133 DBMET01538 | DBMET01537 | |
| 0.098 | 0.124 | 0.268 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.248 0.037 DBMET01536 0.268 0.033 DBMET01537 0.196 0.052 DBMET01538 | DBMET01537 | |
| 0.07 | 0.098 | 0.155 | Vascular endothelial growth factor 1 antagonist | 0.155 0.039 DBMET01536 0.119 0.055 DBMET01537 0.127 0.051 DBMET01538 | DBMET01536 | |
| 0.054 | 0.081 | 0.1 | Histone deacetylase SIRT1 stimulant | 0.072 0.052 DBMET01533 0.074 0.051 DBMET01536 0.1 0.028 DBMET01537 0.1 0.028 DBMET01538 | DBMET01538 | |
| 0.054 | 0.081 | 0.1 | Histone deacetylase stimulant | 0.072 0.052 DBMET01533 0.074 0.051 DBMET01536 0.1 0.028 DBMET01537 0.1 0.028 DBMET01538 | DBMET01538 | |
| 0.04 | 0.068 | 0.075 | Fibroblast growth factor 4 antagonist | 0.073 0.024 DBMET01536 0.075 0.022 DBMET01538 | DBMET01538 | |
| 0.039 | 0.069 | 0.118 | Tyk2 inhibitor | 0.114 0.022 DBMET01536 0.118 0.021 DBMET01537 0.063 0.046 DBMET01538 | DBMET01537 | |
| 0.038 | 0.069 | 0.056 | CXC chemokine 1 receptor antagonist | 0.056 0.027 DBMET01533 0.054 0.03 DBMET01537 0.055 0.029 DBMET01538 | DBMET01533 | |
| 0.05 | 0.083 | 0.079 | ZAP-70 protein tyrosine kinase inhibitor | 0.077 0.039 DBMET01536 0.079 0.036 DBMET01538 | DBMET01538 | |
| 0.043 | 0.077 | 0.071 | Botulinum neurotoxin type A inhibitor | 0.065 0.031 DBMET01533 0.056 0.045 DBMET01535 0.071 0.024 DBMET01537 0.052 0.051 DBMET01538 | DBMET01537 | |
| 0.063 | 0.099 | 0.185 | Fibroblast growth factor 1 antagonist | 0.185 0.02 DBMET01536 0.121 0.043 DBMET01537 0.163 0.027 DBMET01538 0.155 0.029 DBMET01539 | DBMET01536 | |
| 0.047 | 0.087 | 0.089 | Corticotropin releasing factor 2 receptor antagonist | 0.089 0.011 DBMET01536 0.074 0.023 DBMET01537 0.07 0.029 DBMET01538 | DBMET01536 | |
| 0.079 | 0.12 | 0.125 | Glutamate (mGluR7) agonist | 0.096 0.07 DBMET01534 0.125 0.026 DBMET01536 0.094 0.072 DBMET01538 | DBMET01536 | |
| 0.008 | 0.052 | 0.032 | Integrin beta3 antagonist | 0.032 0.009 DBMET01535 | DBMET01535 | |
| 0.05 | 0.094 | 0.174 | Rho-associated kinase I inhibitor | 0.174 0.011 DBMET01536 0.115 0.023 DBMET01537 0.072 0.054 DBMET01538 | DBMET01536 | |
| 0.081 | 0.126 | 0.157 | Cyclin-dependent kinase 7 inhibitor | 0.147 0.061 DBMET01536 0.157 0.055 DBMET01537 0.119 0.085 DBMET01538 | DBMET01537 | |
| 0.126 | 0.172 | 0.159 | Cyclin-dependent kinase 3 inhibitor | 0.154 0.086 DBMET01536 0.159 0.077 DBMET01537 0.147 0.103 DBMET01538 | DBMET01537 | |
| 0.112 | 0.162 | 0.161 | MAP kinase 3 inhibitor | 0.161 0.052 DBMET01536 0.156 0.059 DBMET01537 0.136 0.092 DBMET01538 | DBMET01536 | |
| 0.103 | 0.158 | 0.2 | TRKC antagonist | 0.183 0.077 DBMET01536 0.2 0.067 DBMET01537 0.13 0.12 DBMET01538 | DBMET01537 | |
| 0.051 | 0.109 | 0.07 | Focal adhesion kinase 1 inhibitor | 0.07 0.062 DBMET01536 | DBMET01536 | |
| 0.041 | 0.099 | 0.08 | Macrophage colony-stimulating factor 1 receptor antagonist | 0.08 0.041 DBMET01536 | DBMET01536 | |
| 0.023 | 0.085 | 0.059 | Glutamate (mGluR5) antagonist | 0.059 0.023 DBMET01536 0.046 0.033 DBMET01537 | DBMET01536 | |
| 0.044 | 0.107 | 0.066 | Histone deacetylase SIRT2 inhibitor | 0.066 0.06 DBMET01537 | DBMET01537 | |
| 0.121 | 0.185 | 0.168 | Heat shock protein 70 antagonist | 0.13 0.123 DBMET01533 0.168 0.019 DBMET01535 0.137 0.086 DBMET01536 0.148 0.051 DBMET01537 0.138 0.082 DBMET01538 | DBMET01535 | |
| 0.118 | 0.186 | 0.251 | Focal adhesion kinase 2 inhibitor | 0.251 0.037 DBMET01536 0.17 0.1 DBMET01537 0.194 0.074 DBMET01538 | DBMET01536 | |
| 0.036 | 0.107 | 0.077 | Epithelial sodium channel blocker | 0.077 0.014 DBMET01535 | DBMET01535 | |
| 0.052 | 0.126 | 0.117 | Insulin like growth factor 1 antagonist | 0.117 0.031 DBMET01536 0.077 0.065 DBMET01537 0.078 0.063 DBMET01538 | DBMET01536 | |
| 0.042 | 0.117 | 0.096 | Fibroblast growth factor 3 antagonist | 0.096 0.035 DBMET01536 | DBMET01536 | |
| 0.054 | 0.13 | 0.084 | Platelet activating factor alpha antagonist | 0.084 0.075 DBMET01536 | DBMET01536 | |
| 0.079 | 0.156 | 0.216 | Tyrosine kinase inhibitor | 0.216 0.063 DBMET01536 0.185 0.074 DBMET01537 0.13 0.101 DBMET01538 | DBMET01536 | |
| 0.051 | 0.129 | 0.126 | Insulin growth factor antagonist | 0.126 0.03 DBMET01536 0.086 0.059 DBMET01537 0.092 0.053 DBMET01538 | DBMET01536 | |
| 0.055 | 0.133 | 0.132 | Check point kinase 2 inhibitor | 0.132 0.04 DBMET01534 | DBMET01534 | |
| 0.02 | 0.099 | 0.068 | Factor XIa inhibitor | 0.068 0.01 DBMET01535 | DBMET01535 | |
| 0.062 | 0.142 | 0.115 | Polo-like kinase-1 inhibitor | 0.115 0.033 DBMET01536 0.09 0.062 DBMET01537 0.088 0.066 DBMET01538 | DBMET01536 | |
| 0.056 | 0.136 | 0.238 | HIV-1 integrase (Overall Integration) inhibitor | 0.082 0.075 DBMET01533 0.238 0.006 DBMET01535 0.086 0.069 DBMET01536 0.129 0.034 DBMET01537 0.093 0.061 DBMET01538 | DBMET01535 | |
| 0.045 | 0.126 | 0.098 | Secretase beta inhibitor | 0.098 0.019 DBMET01536 0.089 0.026 DBMET01537 0.075 0.042 DBMET01538 | DBMET01536 | |
| 0.049 | 0.132 | 0.139 | Aurora-A kinase inhibitor | 0.139 0.045 DBMET01536 0.119 0.055 DBMET01537 | DBMET01536 | |
| 0.017 | 0.101 | 0.056 | Factor XI inhibitor | 0.056 0.008 DBMET01535 | DBMET01535 | |
| 0.109 | 0.194 | 0.132 | CC chemokine 6 receptor antagonist | 0.132 0.064 DBMET01535 0.125 0.093 DBMET01537 | DBMET01535 | |
| 0.116 | 0.202 | 0.168 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.158 0.133 DBMET01536 0.168 0.12 DBMET01537 | DBMET01537 | |
| 0.069 | 0.155 | 0.205 | Vascular endothelial growth factor 3 antagonist | 0.205 0.04 DBMET01536 0.14 0.074 DBMET01537 0.189 0.046 DBMET01538 | DBMET01536 | |
| 0.055 | 0.142 | 0.189 | Granulocyte macrophage colony stimulating factor antagonist | 0.189 0.025 DBMET01536 0.103 0.068 DBMET01537 | DBMET01536 | |
| 0.018 | 0.107 | 0.091 | Phosphorylase inhibitor | 0.039 0.038 DBMET01535 0.04 0.037 DBMET01536 0.091 0.014 DBMET01537 | DBMET01537 | |
| 0.104 | 0.193 | 0.177 | CF transmembrane conductance regulator agonist | 0.16 0.06 DBMET01536 0.177 0.039 DBMET01537 0.167 0.05 DBMET01538 | DBMET01537 | |
| 0.042 | 0.133 | 0.109 | Potassium channel large-conductance Ca-activated activator | 0.063 0.055 DBMET01535 0.077 0.037 DBMET01537 0.109 0.02 DBMET01538 | DBMET01538 | |
| 0.034 | 0.125 | 0.068 | Raf kinase inhibitor | 0.066 0.059 DBMET01536 0.068 0.056 DBMET01537 | DBMET01537 | |
| 0.056 | 0.148 | 0.135 | Vascular endothelial growth factor antagonist | 0.135 0.061 DBMET01536 0.094 0.087 DBMET01537 0.094 0.087 DBMET01538 | DBMET01536 | |
| 0.103 | 0.197 | 0.171 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.171 0.041 DBMET01535 0.135 0.104 DBMET01536 0.137 0.099 DBMET01537 0.128 0.123 DBMET01538 | DBMET01535 | |
| 0.067 | 0.163 | 0.149 | Ribosomal protein S6 kinase inhibitor | 0.133 0.078 DBMET01536 0.149 0.065 DBMET01537 | DBMET01537 | |
| 0.072 | 0.168 | 0.136 | Sodium channel blocker | 0.136 0.068 DBMET01534 0.122 0.081 DBMET01536 | DBMET01534 | |
| 0.02 | 0.117 | 0.059 | Phosphodiesterase 4A inhibitor | 0.059 0.03 DBMET01536 | DBMET01536 | |
| 0.103 | 0.202 | 0.907 | Aldehyde oxidase inhibitor | 0.18 0.116 DBMET01533 0.907 0.003 DBMET01535 0.173 0.121 DBMET01537 | DBMET01535 | |
| 0.088 | 0.188 | 0.235 | Hexokinase inhibitor | 0.125 0.11 DBMET01533 0.155 0.073 DBMET01535 0.191 0.041 DBMET01536 0.235 0.02 DBMET01537 0.208 0.031 DBMET01538 | DBMET01537 | |
| 0.012 | 0.113 | 0.094 | Diamine oxidase inhibitor | 0.094 0.004 DBMET01535 | DBMET01535 | |
| 0.126 | 0.227 | 0.241 | 5 Hydroxytryptamine 1E antagonist | 0.241 0.085 DBMET01536 0.222 0.105 DBMET01537 0.205 0.125 DBMET01538 | DBMET01536 | |
| 0.038 | 0.14 | 0.081 | Platelet growth factor antagonist | 0.081 0.056 DBMET01536 | DBMET01536 | |
| 0.114 | 0.217 | 0.167 | Death-associated protein kinase 2 inhibitor | 0.138 0.137 DBMET01533 0.139 0.135 DBMET01536 0.167 0.073 DBMET01537 | DBMET01537 | |
| 0.045 | 0.148 | 0.118 | Vascular endothelial growth factor 2 antagonist | 0.118 0.061 DBMET01536 | DBMET01536 | |
| 0.042 | 0.149 | 0.091 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | 0.087 0.065 DBMET01536 0.091 0.062 DBMET01537 | DBMET01537 | |
| 0.038 | 0.146 | 0.128 | MAP kinase 10 inhibitor | 0.128 0.021 DBMET01536 0.122 0.023 DBMET01537 | DBMET01536 | |
| 0.071 | 0.18 | 0.241 | CDC-like kinase 2 inhibitor | 0.241 0.048 DBMET01536 0.236 0.051 DBMET01537 0.145 0.096 DBMET01538 | DBMET01536 | |
| 0.102 | 0.211 | 0.24 | Death-associated protein kinase 3 inhibitor | 0.204 0.072 DBMET01536 0.24 0.056 DBMET01537 0.151 0.12 DBMET01538 | DBMET01537 | |
| 0.096 | 0.207 | 0.317 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.268 0.06 DBMET01536 0.317 0.045 DBMET01537 0.261 0.063 DBMET01538 | DBMET01537 | |
| 0.06 | 0.173 | 0.129 | MAP kinase kinase 1 inhibitor | 0.109 0.046 DBMET01535 0.111 0.044 DBMET01536 0.129 0.028 DBMET01537 | DBMET01537 | |
| 0.019 | 0.132 | 0.072 | Glutamate (mGluR4) agonist | 0.052 0.01 DBMET01536 0.072 0.006 DBMET01537 0.049 0.011 DBMET01538 | DBMET01537 | |
| 0.04 | 0.154 | 0.189 | Potassium channel (Ca-activated) activator | 0.131 0.035 DBMET01535 0.118 0.042 DBMET01536 0.189 0.017 DBMET01537 0.171 0.021 DBMET01538 | DBMET01537 | |
| 0.098 | 0.212 | 0.328 | Dyrk kinase inhibitor | 0.289 0.056 DBMET01536 0.328 0.043 DBMET01537 0.262 0.067 DBMET01538 | DBMET01537 | |
| 0.089 | 0.209 | 0.283 | Hemostatic | 0.177 0.044 DBMET01535 0.15 0.067 DBMET01536 0.182 0.041 DBMET01537 0.283 0.018 DBMET01539 | DBMET01539 | |
| 0.07 | 0.19 | 0.123 | CDK3/cyclin E inhibitor | 0.108 0.072 DBMET01536 0.123 0.051 DBMET01537 | DBMET01537 | |
| 0.155 | 0.275 | 0.294 | Transcription factor inhibitor | 0.294 0.158 DBMET01536 0.246 0.189 DBMET01537 0.247 0.189 DBMET01538 | DBMET01536 | |
| 0.056 | 0.176 | 0.189 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | 0.129 0.074 DBMET01536 0.189 0.045 DBMET01537 0.115 0.086 DBMET01538 | DBMET01537 | |
| 0.012 | 0.133 | 0.043 | Proto-oncogene tyrosine-protein kinase Met inhibitor | 0.043 0.038 DBMET01536 | DBMET01536 | |
| 0.031 | 0.154 | 0.056 | Sodium/calcium exchanger inhibitor | 0.056 0.024 DBMET01536 0.05 0.034 DBMET01537 | DBMET01536 | |
| 0.081 | 0.204 | 0.176 | Protein kinase (CK1) gamma 3 inhibitor | 0.164 0.074 DBMET01536 0.176 0.064 DBMET01537 0.14 0.101 DBMET01538 | DBMET01537 | |
| 0.08 | 0.204 | 0.312 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.289 0.03 DBMET01536 0.312 0.024 DBMET01537 0.19 0.084 DBMET01538 | DBMET01537 | |
| 0.065 | 0.19 | 0.149 | Cytokine production inhibitor | 0.149 0.063 DBMET01536 | DBMET01536 | |
| 0.05 | 0.175 | 0.199 | Aurora-B kinase inhibitor | 0.199 0.031 DBMET01536 0.139 0.052 DBMET01537 | DBMET01536 | |
| 0.025 | 0.155 | 0.094 | Prostaglandin-E synthase inhibitor | 0.067 0.052 DBMET01536 0.094 0.03 DBMET01537 | DBMET01537 | |
| 0.051 | 0.182 | 0.122 | Protein-tyrosine kinase Lyn inhibitor | 0.122 0.084 DBMET01536 | DBMET01536 | |
| 0.057 | 0.189 | 0.241 | MAP kinase kinase inhibitor | 0.171 0.041 DBMET01536 0.241 0.017 DBMET01537 | DBMET01537 | |
| 0.1 | 0.234 | 0.232 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.207 0.071 DBMET01536 0.232 0.058 DBMET01537 0.143 0.137 DBMET01538 | DBMET01537 | |
| 0.078 | 0.212 | 0.166 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.149 0.095 DBMET01536 0.166 0.083 DBMET01537 | DBMET01537 | |
| 0.066 | 0.201 | 0.23 | Protein kinase C nu inhibitor | 0.206 0.045 DBMET01536 0.23 0.038 DBMET01537 | DBMET01537 | |
| 0.043 | 0.182 | 0.101 | Hepatocyte growth factor antagonist | 0.101 0.05 DBMET01536 0.099 0.052 DBMET01537 | DBMET01536 | |
| 0.049 | 0.189 | 0.198 | Cyclin-dependent kinase 9 inhibitor | 0.198 0.023 DBMET01536 0.195 0.024 DBMET01537 0.137 0.038 DBMET01538 | DBMET01536 | |
| 0.056 | 0.197 | 0.074 | MAP kinase 7 inhibitor | 0.074 0.068 DBMET01536 | DBMET01536 | |
| 0.054 | 0.195 | 0.121 | Lck kinase inhibitor | 0.121 0.084 DBMET01536 0.102 0.1 DBMET01537 | DBMET01536 | |
| 0.015 | 0.156 | 0.04 | Stearoyl-CoA desaturase inhibitor | 0.04 0.038 DBMET01537 | DBMET01537 | |
| 0.117 | 0.259 | 0.218 | MAP-kinase-activated kinase 5 inhibitor | 0.169 0.149 DBMET01536 0.218 0.084 DBMET01537 | DBMET01537 | |
| 0.06 | 0.202 | 0.147 | Growth factor antagonist | 0.147 0.071 DBMET01536 0.109 0.104 DBMET01537 0.113 0.099 DBMET01538 | DBMET01536 | |
| 0.034 | 0.177 | 0.074 | Glutamate (mGluR group I) antagonist | 0.074 0.044 DBMET01536 0.064 0.057 DBMET01537 | DBMET01536 | |
| 0.043 | 0.188 | 0.134 | Falcipain 3 inhibitor | 0.134 0.045 DBMET01535 | DBMET01535 | |
| 0.061 | 0.207 | 0.121 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.105 0.098 DBMET01536 0.121 0.083 DBMET01537 | DBMET01537 | |
| 0.082 | 0.228 | 0.153 | Polo-like kinase-3 inhibitor | 0.151 0.083 DBMET01536 0.153 0.081 DBMET01537 | DBMET01537 | |
| 0.108 | 0.256 | 0.247 | DNA damaging | 0.247 0.082 DBMET01535 | DBMET01535 | |
| 0.047 | 0.195 | 0.21 | Glycogen synthase kinase-3 alpha inhibitor | 0.174 0.051 DBMET01536 0.21 0.039 DBMET01537 0.11 0.093 DBMET01538 | DBMET01537 | |
| 0.02 | 0.17 | 0.105 | Glutamate (mGluR group III) agonist | 0.089 0.011 DBMET01536 0.105 0.009 DBMET01537 0.084 0.012 DBMET01538 | DBMET01537 | |
| 0.027 | 0.18 | 0.078 | Fibroblast growth factor 2 antagonist | 0.078 0.035 DBMET01536 | DBMET01536 | |
| 0.052 | 0.206 | 0.104 | Histone deacetylase class III inhibitor | 0.104 0.086 DBMET01537 | DBMET01537 | |
| 0.098 | 0.252 | 0.181 | ATPase inhibitor | 0.169 0.073 DBMET01536 0.181 0.057 DBMET01537 | DBMET01537 | |
| 0.064 | 0.22 | 0.102 | Folate antagonist | 0.102 0.061 DBMET01535 | DBMET01535 | |
| 0.019 | 0.175 | 0.051 | Phosphodiesterase 4C inhibitor | 0.051 0.044 DBMET01536 | DBMET01536 | |
| 0.054 | 0.211 | 0.202 | Tyrosine-protein kinase receptor antagonist | 0.202 0.04 DBMET01536 0.172 0.053 DBMET01537 | DBMET01536 | |
| 0.076 | 0.233 | 0.245 | LIM domain kinase 1 inhibitor | 0.233 0.047 DBMET01536 0.245 0.041 DBMET01537 0.143 0.105 DBMET01538 | DBMET01537 | |
| 0.017 | 0.175 | 0.04 | MAP3K5 inhibitor | 0.037 0.03 DBMET01536 0.04 0.025 DBMET01537 | DBMET01537 | |
| 0.042 | 0.202 | 0.226 | MAP kinase 8 inhibitor | 0.226 0.013 DBMET01536 0.215 0.014 DBMET01537 | DBMET01536 | |
| 0.062 | 0.226 | 0.201 | CDC-like kinase 4 inhibitor | 0.201 0.067 DBMET01536 0.175 0.082 DBMET01537 | DBMET01536 | |
| 0.04 | 0.208 | 0.323 | MAP kinase 9 inhibitor | 0.318 0.01 DBMET01536 0.323 0.01 DBMET01537 | DBMET01537 | |
| 0.023 | 0.191 | 0.084 | Phosphodiesterase 4D inhibitor | 0.084 0.045 DBMET01536 | DBMET01536 | |
| 0.064 | 0.234 | 0.149 | Protein kinase (CK1) gamma 1 inhibitor | 0.135 0.082 DBMET01536 0.149 0.07 DBMET01537 | DBMET01537 | |
| 0.026 | 0.197 | 0.081 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | 0.077 0.057 DBMET01536 0.081 0.051 DBMET01537 | DBMET01537 | |
| 0.031 | 0.204 | 0.095 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.061 0.042 DBMET01536 0.095 0.012 DBMET01537 | DBMET01537 | |
| 0.043 | 0.218 | 0.298 | Cholesterol synthesis inhibitor | 0.298 0.012 DBMET01535 | DBMET01535 | |
| 0.073 | 0.251 | 0.199 | Cyclin-dependent kinase 8 inhibitor | 0.171 0.06 DBMET01536 0.199 0.036 DBMET01537 0.158 0.071 DBMET01538 | DBMET01537 | |
| 0.137 | 0.316 | 0.273 | Caspase 3 stimulant | 0.273 0.095 DBMET01536 0.262 0.103 DBMET01537 0.236 0.126 DBMET01538 | DBMET01536 | |
| 0.058 | 0.238 | 0.218 | Clk dual-specificity kinase inhibitor | 0.218 0.069 DBMET01536 0.195 0.082 DBMET01537 0.146 0.118 DBMET01538 | DBMET01536 | |
| 0.15 | 0.33 | 0.217 | MAP kinase kinase 3 inhibitor | 0.217 0.08 DBMET01536 0.216 0.083 DBMET01537 0.191 0.151 DBMET01538 | DBMET01536 | |
| 0.058 | 0.238 | 0.127 | Glutamate release inhibitor | 0.127 0.018 DBMET01535 0.096 0.049 DBMET01536 | DBMET01535 | |
| 0.036 | 0.218 | 0.059 | Bcl-xL inhibitor | 0.059 0.042 DBMET01535 | DBMET01535 | |
| 0.048 | 0.231 | 0.101 | Epidermal growth factor receptor kinase inhibitor | 0.101 0.096 DBMET01536 | DBMET01536 | |
| 0.016 | 0.201 | 0.047 | Dihydrofolate reductase inhibitor | 0.047 0.023 DBMET01536 | DBMET01536 | |
| 0.005 | 0.19 | 0.03 | CXC chemokine 2 receptor antagonist | 0.03 0.014 DBMET01537 | DBMET01537 | |
| 0.027 | 0.215 | 0.082 | Dihydroorotate oxidase inhibitor | 0.062 0.026 DBMET01535 0.054 0.041 DBMET01536 0.082 0.009 DBMET01537 0.052 0.044 DBMET01538 | DBMET01537 | |
| 0.007 | 0.196 | 0.034 | Methionyl aminopeptidase 1 inhibitor | 0.032 0.023 DBMET01536 0.034 0.018 DBMET01537 | DBMET01537 | |
| 0.044 | 0.234 | 0.191 | TRKA antagonist | 0.191 0.033 DBMET01536 0.171 0.039 DBMET01537 0.105 0.083 DBMET01538 | DBMET01536 | |
| 0.05 | 0.239 | 0.212 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.189 0.069 DBMET01536 0.212 0.059 DBMET01537 | DBMET01537 | |
| 0.026 | 0.216 | 0.066 | MAP3K7 inhibitor | 0.066 0.062 DBMET01537 | DBMET01537 | |
| 0.119 | 0.31 | 0.194 | ErbB-1 antagonist | 0.194 0.096 DBMET01536 0.185 0.108 DBMET01537 0.167 0.139 DBMET01538 | DBMET01536 | |
| 0.03 | 0.223 | 0.141 | Protein kinase (CK1) delta inhibitor | 0.141 0.058 DBMET01536 0.139 0.06 DBMET01537 | DBMET01536 | |
| 0.049 | 0.243 | 0.128 | Protein kinase (CK1) gamma inhibitor | 0.125 0.085 DBMET01536 0.128 0.082 DBMET01537 | DBMET01537 | |
| 0.04 | 0.236 | 0.208 | Cystathionine beta-synthase inhibitor | 0.208 0.023 DBMET01535 0.104 0.072 DBMET01536 0.175 0.031 DBMET01537 0.16 0.037 DBMET01538 | DBMET01535 | |
| 0.043 | 0.244 | 0.139 | Protein kinase C gamma inhibitor | 0.139 0.038 DBMET01535 0.104 0.07 DBMET01537 | DBMET01535 | |
| 0.003 | 0.205 | 0.02 | Cyclin T1 inhibitor | 0.02 0.011 DBMET01537 | DBMET01537 | |
| 0.095 | 0.297 | 0.162 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.162 0.116 DBMET01536 0.148 0.136 DBMET01537 | DBMET01536 | |
| 0.008 | 0.212 | 0.111 | Beta tubulin antagonist | 0.053 0.044 DBMET01536 0.111 0.019 DBMET01538 | DBMET01538 | |
| 0.077 | 0.282 | 0.167 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.141 0.121 DBMET01536 0.167 0.098 DBMET01537 | DBMET01537 | |
| 0.018 | 0.226 | 0.064 | Purinergic P2X2 antagonist | 0.058 0.053 DBMET01538 0.064 0.049 DBMET01539 | DBMET01539 | |
| 0.043 | 0.253 | 0.103 | Beta glucuronidase inhibitor | 0.103 0.065 DBMET01535 | DBMET01535 | |
| 0.07 | 0.28 | 0.255 | I kappa B kinase epsilon inhibitor | 0.255 0.035 DBMET01536 0.22 0.055 DBMET01537 0.212 0.061 DBMET01538 | DBMET01536 | |
| 0.045 | 0.256 | 0.205 | Thrombolytic | 0.205 0.05 DBMET01535 | DBMET01535 | |
| 0.052 | 0.264 | 0.095 | Estrogen-related receptor beta agonist | 0.095 0.032 DBMET01535 0.088 0.045 DBMET01537 | DBMET01535 | |
| 0.044 | 0.258 | 0.151 | DNA polymerase I inhibitor | 0.151 0.049 DBMET01535 | DBMET01535 | |
| 0.07 | 0.284 | 0.138 | NOS3 expression enhancer | 0.138 0.086 DBMET01537 | DBMET01537 | |
| 0.033 | 0.247 | 0.089 | Urease inhibitor | 0.089 0.079 DBMET01535 | DBMET01535 | |
| 0.042 | 0.265 | 0.166 | Multidrug resistance-associated protein 1 inhibitor | 0.166 0.019 DBMET01539 | DBMET01539 | |
| 0.066 | 0.29 | 0.301 | MAP kinase kinase 2 inhibitor | 0.263 0.048 DBMET01536 0.301 0.035 DBMET01537 0.267 0.047 DBMET01538 | DBMET01537 | |
| 0.012 | 0.236 | 0.142 | Alpha tubulin antagonist | 0.054 0.036 DBMET01536 0.048 0.044 DBMET01537 0.142 0.01 DBMET01539 | DBMET01539 | |
| 0.024 | 0.251 | 0.049 | CC chemokine receptor 2B antagonist | 0.049 0.034 DBMET01536 0.047 0.038 DBMET01537 | DBMET01536 | |
| 0.062 | 0.29 | 0.126 | Factor V inhibitor | 0.126 0.033 DBMET01535 | DBMET01535 | |
| 0.036 | 0.266 | 0.102 | TRKB antagonist | 0.102 0.098 DBMET01536 | DBMET01536 | |
| 0.014 | 0.246 | 0.098 | Maillard reaction inhibitor | 0.098 0.017 DBMET01535 | DBMET01535 | |
| 0.041 | 0.275 | 0.101 | MAP kinase 13 inhibitor | 0.101 0.08 DBMET01537 | DBMET01537 | |
| 0.026 | 0.261 | 0.14 | MAP kinase kinase kinase inhibitor | 0.118 0.052 DBMET01536 0.14 0.04 DBMET01537 | DBMET01537 | |
| 0.02 | 0.255 | 0.116 | Phosphodiesterase IV inhibitor | 0.116 0.035 DBMET01536 | DBMET01536 | |
| 0.036 | 0.276 | 0.171 | 5 Hydroxytryptamine 3A agonist | 0.134 0.045 DBMET01536 0.171 0.025 DBMET01537 | DBMET01537 | |
| 0.066 | 0.313 | 0.374 | Interleukin 6 antagonist | 0.374 0.009 DBMET01534 | DBMET01534 | |
| 0.058 | 0.304 | 0.291 | Heat shock protein 90 alpha antagonist | 0.218 0.04 DBMET01536 0.291 0.016 DBMET01537 0.262 0.023 DBMET01538 | DBMET01537 | |
| 0.007 | 0.259 | 0.058 | Dihydropteroate synthase inhibitor | 0.058 0.012 DBMET01535 0.036 0.032 DBMET01537 | DBMET01535 | |
| 0.033 | 0.285 | 0.235 | Tubulin antagonist | 0.14 0.063 DBMET01536 0.196 0.038 DBMET01538 0.235 0.028 DBMET01539 | DBMET01539 | |
| 0.011 | 0.264 | 0.133 | NMDA receptor subunit 3B antagonist | 0.133 0.008 DBMET01535 | DBMET01535 | |
| 0.027 | 0.284 | 0.142 | Protein kinase (CK1) inhibitor | 0.139 0.076 DBMET01536 0.142 0.074 DBMET01537 | DBMET01537 | |
| 0.019 | 0.277 | 0.06 | Cyclin D1 inhibitor | 0.06 0.043 DBMET01536 0.057 0.048 DBMET01538 | DBMET01536 | |
| 0.03 | 0.291 | 0.143 | Glutamate receptor antagonist | 0.143 0.056 DBMET01537 | DBMET01537 | |
| 0.044 | 0.307 | 0.144 | Activin receptor-like kinase 2 inhibitor | 0.144 0.072 DBMET01536 | DBMET01536 | |
| 0.138 | 0.402 | 0.458 | MAP kinase 1 inhibitor | 0.458 0.073 DBMET01536 0.347 0.138 DBMET01537 0.318 0.161 DBMET01538 | DBMET01536 | |
| 0.067 | 0.331 | 0.211 | Non-steroidal antiinflammatory agent | 0.159 0.105 DBMET01534 0.211 0.062 DBMET01535 | DBMET01535 | |
| 0.009 | 0.278 | 0.084 | NMDA 2C receptor antagonist | 0.084 0.023 DBMET01535 0.071 0.032 DBMET01537 | DBMET01535 | |
| 0.031 | 0.301 | 0.105 | Nitric-oxide synthase inhibitor | 0.105 0.052 DBMET01535 | DBMET01535 | |
| 0.057 | 0.33 | 0.283 | Antimitotic | 0.248 0.06 DBMET01536 0.163 0.109 DBMET01537 0.283 0.049 DBMET01538 0.204 0.082 DBMET01539 | DBMET01538 | |
| 0.023 | 0.296 | 0.135 | M18 aspartyl aminopeptidase inhibitor | 0.123 0.068 DBMET01537 0.135 0.06 DBMET01538 | DBMET01538 | |
| 0.032 | 0.306 | 0.058 | Immunoglobulin Fc receptor antagonist | 0.055 0.038 DBMET01536 0.058 0.03 DBMET01537 | DBMET01537 | |
| 0.066 | 0.341 | 0.302 | Tumour necrosis factor alpha release inhibitor | 0.302 0.052 DBMET01534 | DBMET01534 | |
| 0.006 | 0.288 | 0.154 | NMDA 2 receptor antagonist | 0.154 0.016 DBMET01535 0.065 0.056 DBMET01537 | DBMET01535 | |
| 0.024 | 0.311 | 0.144 | Histamine N-methyltransferase inhibitor | 0.144 0.016 DBMET01535 | DBMET01535 | |
| 0.02 | 0.309 | 0.059 | Topoisomerase II beta inhibitor | 0.059 0.023 DBMET01535 | DBMET01535 | |
| 0.019 | 0.308 | 0.095 | Cyclin-dependent kinase 5 inhibitor | 0.095 0.079 DBMET01537 | DBMET01537 | |
| 0.026 | 0.32 | 0.082 | MAP-kinase-activated kinase inhibitor | 0.082 0.059 DBMET01536 0.082 0.059 DBMET01537 | DBMET01537 | |
| 0.037 | 0.333 | 0.166 | Beta amyloid protein antagonist | 0.166 0.03 DBMET01536 0.126 0.062 DBMET01537 0.156 0.037 DBMET01538 0.097 0.094 DBMET01539 | DBMET01536 | |
| 0.015 | 0.312 | 0.132 | Neuraminidase (influenza) inhibitor | 0.132 0.009 DBMET01535 | DBMET01535 | |
| 0.043 | 0.341 | 0.113 | D-Ala-D-Ala ligase inhibitor | 0.097 0.033 DBMET01535 0.09 0.045 DBMET01536 0.113 0.017 DBMET01537 0.096 0.034 DBMET01538 | DBMET01537 | |
| 0.02 | 0.318 | 0.072 | MAP-kinase-activated kinase 2 inhibitor | 0.072 0.054 DBMET01536 0.071 0.056 DBMET01537 | DBMET01536 | |
| 0.019 | 0.317 | 0.049 | Heparanase inhibitor | 0.049 0.048 DBMET01535 | DBMET01535 | |
| 0.013 | 0.312 | 0.079 | Neuraminidase (Influenza A) inhibitor | 0.079 0.005 DBMET01535 | DBMET01535 | |
| 0.059 | 0.363 | 0.176 | Streptokinase A inhibitor | 0.164 0.159 DBMET01537 0.176 0.15 DBMET01538 | DBMET01538 | |
| 0.008 | 0.313 | 0.041 | Purinergic P2Y14 antagonist | 0.041 0.01 DBMET01535 | DBMET01535 | |
| 0.015 | 0.321 | 0.237 | Histidine decarboxylase inhibitor | 0.237 0.01 DBMET01535 0.096 0.033 DBMET01537 0.064 0.057 DBMET01538 | DBMET01535 | |
| 0.027 | 0.334 | 0.074 | Adenosine A3 receptor antagonist | 0.074 0.051 DBMET01536 0.073 0.054 DBMET01537 | DBMET01536 | |
| 0.02 | 0.331 | 0.116 | Heat shock protein 90 beta antagonist | 0.056 0.046 DBMET01536 0.088 0.016 DBMET01537 0.116 0.007 DBMET01538 | DBMET01538 | |
| 0.021 | 0.334 | 0.101 | Pim-3 kinase inhibitor | 0.091 0.057 DBMET01536 0.101 0.045 DBMET01537 | DBMET01537 | |
| 0.009 | 0.326 | 0.035 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | 0.035 0.029 DBMET01535 | DBMET01535 | |
| 0.08 | 0.4 | 0.417 | 15-Lipoxygenase inhibitor | 0.335 0.108 DBMET01536 0.417 0.067 DBMET01537 0.406 0.072 DBMET01538 0.293 0.136 DBMET01539 | DBMET01537 | |
| 0.007 | 0.329 | 0.051 | NMDA 2D receptor antagonist | 0.051 0.007 DBMET01535 | DBMET01535 | |
| 0.022 | 0.344 | 0.155 | I kappa B kinase inhibitor | 0.105 0.035 DBMET01536 0.155 0.015 DBMET01537 0.076 0.067 DBMET01538 | DBMET01537 | |
| 0.015 | 0.342 | 0.115 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.115 0.002 DBMET01535 0.045 0.021 DBMET01537 0.051 0.014 DBMET01538 | DBMET01535 | |
| 0.004 | 0.331 | 0.032 | Retinoic acid alpha receptor antagonist | 0.032 0.005 DBMET01535 | DBMET01535 | |
| 0.005 | 0.333 | 0.095 | NMDA receptor subunit 3A antagonist | 0.095 0.009 DBMET01535 | DBMET01535 | |
| 0.012 | 0.342 | 0.1 | Leukotriene B4 antagonist | 0.1 0.01 DBMET01535 | DBMET01535 | |
| 0.012 | 0.344 | 0.038 | Purinergic P2Y2 antagonist | 0.038 0.017 DBMET01539 | DBMET01539 | |
| 0.02 | 0.352 | 0.092 | Protein kinase C zeta inhibitor | 0.092 0.062 DBMET01537 0.086 0.073 DBMET01539 | DBMET01537 | |
| 0.023 | 0.356 | 0.125 | Alkylator | 0.125 0.063 DBMET01535 | DBMET01535 | |
| 0.026 | 0.361 | 0.066 | Exportin-1 inhibitor | 0.066 0.054 DBMET01536 | DBMET01536 | |
| 0.038 | 0.377 | 0.225 | Dual specificity phosphatase 3 inhibitor | 0.225 0.049 DBMET01539 | DBMET01539 | |
| 0.013 | 0.356 | 0.055 | Protein kinase C eta inhibitor | 0.055 0.038 DBMET01535 | DBMET01535 | |
| 0.01 | 0.353 | 0.088 | Leukotriene antagonist | 0.088 0.027 DBMET01535 | DBMET01535 | |
| 0.016 | 0.366 | 0.097 | I kappa B kinase 2 inhibitor | 0.062 0.044 DBMET01536 0.097 0.013 DBMET01537 | DBMET01537 | |
| 0.042 | 0.395 | 0.342 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.15 0.142 DBMET01536 0.148 0.145 DBMET01537 0.342 0.052 DBMET01538 | DBMET01538 | |
| 0.052 | 0.409 | 0.191 | Antioxidant | 0.191 0.121 DBMET01535 | DBMET01535 | |
| 0.014 | 0.372 | 0.054 | Sphingosine kinase 2 inhibitor | 0.054 0.04 DBMET01535 | DBMET01535 | |
| 0.011 | 0.371 | 0.066 | CDC7 inhibitor | 0.066 0.049 DBMET01537 | DBMET01537 | |
| 0.011 | 0.371 | 0.147 | Protein kinase (CK2) alpha inhibitor | 0.097 0.079 DBMET01536 0.147 0.044 DBMET01537 | DBMET01537 | |
| 0.034 | 0.397 | 0.143 | Adenylate cyclase inhibitor | 0.143 0.05 DBMET01535 | DBMET01535 | |
| 0.011 | 0.375 | 0.035 | Protein kinase (CK2) beta inhibitor | 0.032 0.025 DBMET01535 0.035 0.018 DBMET01537 | DBMET01537 | |
| 0.004 | 0.371 | 0.043 | Geranyltranstransferase inhibitor | 0.043 0.032 DBMET01535 | DBMET01535 | |
| 0.025 | 0.395 | 0.105 | Cyclooxygenase 1 inhibitor | 0.105 0.095 DBMET01537 | DBMET01537 | |
| 0.02 | 0.393 | 0.101 | Mediator release inhibitor | 0.101 0.069 DBMET01538 | DBMET01538 | |
| 0.035 | 0.409 | 0.142 | Amyloid beta aggregation inhibitor | 0.142 0.114 DBMET01538 | DBMET01538 | |
| 0.008 | 0.384 | 0.03 | Estrogen-related receptor alpha antagonist | 0.03 0.026 DBMET01537 | DBMET01537 | |
| 0.028 | 0.405 | 0.116 | DNA directed RNA polymerase inhibitor | 0.106 0.049 DBMET01536 0.116 0.041 DBMET01537 | DBMET01537 | |
| 0.004 | 0.381 | 0.065 | Cholecystokinin A antagonist | 0.065 0.015 DBMET01539 | DBMET01539 | |
| 0.117 | 0.496 | 0.312 | Caspase 9 stimulant | 0.297 0.197 DBMET01536 0.272 0.227 DBMET01537 0.312 0.181 DBMET01538 | DBMET01538 | |
| 0.053 | 0.433 | 0.148 | Tumour necrosis factor antagonist | 0.148 0.103 DBMET01536 | DBMET01536 | |
| 0.004 | 0.385 | 0.033 | Phosphoglycerate kinase inhibitor | 0.033 0.027 DBMET01535 | DBMET01535 | |
| 0.028 | 0.414 | 0.093 | Bile acid receptor antagonist | 0.093 0.066 DBMET01535 | DBMET01535 | |
| 0.033 | 0.422 | 0.195 | Dual specificity phosphatase inhibitor | 0.13 0.121 DBMET01535 0.195 0.057 DBMET01539 | DBMET01539 | |
| 0.008 | 0.398 | 0.109 | Neuraminidase inhibitor | 0.109 0.012 DBMET01535 | DBMET01535 | |
| 0.026 | 0.418 | 0.089 | GABA B receptor agonist | 0.089 0.026 DBMET01535 0.078 0.047 DBMET01537 | DBMET01535 | |
| 0.002 | 0.395 | 0.017 | Retinoic acid beta receptor antagonist | 0.017 0.005 DBMET01535 | DBMET01535 | |
| 0.036 | 0.43 | 0.098 | TRPA1 agonist | 0.098 0.092 DBMET01535 | DBMET01535 | |
| 0.041 | 0.436 | 0.152 | Interleukin 4 antagonist | 0.152 0.048 DBMET01538 | DBMET01538 | |
| 0.008 | 0.404 | 0.073 | NMDA receptor glycine site agonist | 0.073 0.034 DBMET01535 | DBMET01535 | |
| 0.034 | 0.432 | 0.235 | Heat shock protein 90 antagonist | 0.167 0.058 DBMET01536 0.235 0.025 DBMET01537 0.226 0.028 DBMET01538 | DBMET01537 | |
| 0.006 | 0.405 | 0.077 | NMDA 2A receptor antagonist | 0.077 0.021 DBMET01535 | DBMET01535 | |
| 0.009 | 0.414 | 0.031 | Complement factor 1s inhibitor | 0.031 0.008 DBMET01535 | DBMET01535 | |
| 0.042 | 0.452 | 0.093 | Interleukin 12 antagonist | 0.093 0.066 DBMET01537 | DBMET01537 | |
| 0.037 | 0.449 | 0.15 | Free radical scavenger | 0.15 0.145 DBMET01538 | DBMET01538 | |
| 0.012 | 0.426 | 0.077 | Inducible nitric-oxide synthase inhibitor | 0.077 0.068 DBMET01535 | DBMET01535 | |
| 0.013 | 0.428 | 0.053 | Squalene epoxidase inhibitor | 0.053 0.028 DBMET01535 | DBMET01535 | |
| 0.024 | 0.442 | 0.07 | Adenine nucleotide translocase inhibitor | 0.07 0.015 DBMET01535 | DBMET01535 | |
| 0.009 | 0.431 | 0.034 | Protein kinase C beta I inhibitor | 0.034 0.023 DBMET01535 | DBMET01535 | |
| 0.012 | 0.44 | 0.077 | Protein kinase C beta inhibitor | 0.077 0.034 DBMET01535 | DBMET01535 | |
| 0.038 | 0.468 | 0.147 | Platelet adhesion inhibitor | 0.147 0.109 DBMET01535 | DBMET01535 | |
| 0.022 | 0.456 | 0.112 | Keratolytic | 0.112 0.024 DBMET01535 | DBMET01535 | |
| 0.032 | 0.468 | 0.156 | Interleukin antagonist | 0.156 0.113 DBMET01534 | DBMET01534 | |
| 0.007 | 0.444 | 0.057 | HIV-1 integrase (3'-Processing) inhibitor | 0.057 0.05 DBMET01539 | DBMET01539 | |
| 0.01 | 0.449 | 0.099 | HIV-1 reverse transcriptase inhibitor | 0.079 0.043 DBMET01536 0.099 0.031 DBMET01537 | DBMET01537 | |
| 0.032 | 0.471 | 0.171 | Carbonic anhydrase XV inhibitor | 0.171 0.024 DBMET01535 | DBMET01535 | |
| 0.041 | 0.482 | 0.117 | Transcription factor STAT6 inhibitor | 0.117 0.065 DBMET01537 | DBMET01537 | |
| 0.101 | 0.542 | 0.168 | 5 Hydroxytryptamine 3E antagonist | 0.168 0.142 DBMET01535 | DBMET01535 | |
| 0.006 | 0.449 | 0.05 | HIV-1 integrase (Strand Transfer) inhibitor | 0.05 0.049 DBMET01539 | DBMET01539 | |
| 0.002 | 0.445 | 0.031 | Uridine phosphorylase inhibitor | 0.031 0.017 DBMET01535 | DBMET01535 | |
| 0.059 | 0.504 | 0.219 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.219 0.058 DBMET01535 0.161 0.123 DBMET01537 0.158 0.131 DBMET01538 | DBMET01535 | |
| 0.003 | 0.449 | 0.029 | Retinoic acid receptor antagonist | 0.029 0.006 DBMET01535 | DBMET01535 | |
| 0.007 | 0.455 | 0.108 | Protein kinase (CK2) inhibitor | 0.108 0.057 DBMET01537 | DBMET01537 | |
| 0.041 | 0.495 | 0.212 | 12-Lipoxygenase inhibitor | 0.197 0.155 DBMET01537 0.212 0.138 DBMET01538 | DBMET01538 | |
| 0.007 | 0.463 | 0.028 | Estrogen-related receptor gamma antagonist | 0.028 0.019 DBMET01535 | DBMET01535 | |
| 0.017 | 0.473 | 0.106 | Purinergic P2X1 antagonist | 0.106 0.015 DBMET01535 | DBMET01535 | |
| 0.036 | 0.492 | 0.131 | Thiol protease inhibitor | 0.131 0.094 DBMET01535 | DBMET01535 | |
| 0.004 | 0.466 | 0.021 | Leukotriene B4 receptor 2 antagonist | 0.021 0.017 DBMET01535 | DBMET01535 | |
| 0.038 | 0.501 | 0.158 | GABA C receptor rho-2 antagonist | 0.151 0.073 DBMET01535 0.142 0.085 DBMET01536 0.158 0.063 DBMET01537 0.151 0.073 DBMET01538 | DBMET01537 | |
| 0.042 | 0.506 | 0.151 | 3C-like protease (Human coronavirus) inhibitor | 0.151 0.099 DBMET01536 | DBMET01536 | |
| 0.07 | 0.54 | 0.531 | GABA C receptor rho-3 antagonist | 0.315 0.106 DBMET01535 0.363 0.079 DBMET01536 0.531 0.018 DBMET01537 0.397 0.063 DBMET01538 | DBMET01537 | |
| 0.063 | 0.534 | 0.331 | Insulysin inhibitor | 0.331 0.042 DBMET01535 | DBMET01535 | |
| 0.013 | 0.487 | 0.038 | CF transmembrane conductance regulator antagonist | 0.038 0.033 DBMET01535 | DBMET01535 | |
| 0.026 | 0.501 | 0.231 | Insulin sensitizer | 0.231 0.047 DBMET01535 | DBMET01535 | |
| 0.004 | 0.48 | 0.04 | Cholecystokinin antagonist | 0.04 0.03 DBMET01539 | DBMET01539 | |
| 0.008 | 0.485 | 0.068 | Retinoic acid alpha receptor agonist | 0.068 0.007 DBMET01535 | DBMET01535 | |
| 0.059 | 0.539 | 0.157 | Neurotensin receptor agonist | 0.157 0.085 DBMET01535 0.14 0.129 DBMET01537 | DBMET01535 | |
| 0.002 | 0.483 | 0.015 | Retinoic acid receptor gamma antagonist | 0.015 0.005 DBMET01535 | DBMET01535 | |
| 0.031 | 0.518 | 0.327 | Alpha-glucosidase inhibitor | 0.327 0.147 DBMET01538 | DBMET01538 | |
| 0.084 | 0.573 | 0.337 | Antiinflammatory | 0.337 0.182 DBMET01537 0.317 0.199 DBMET01538 | DBMET01537 | |
| 0.056 | 0.548 | 0.135 | MAP kinase kinase 4 inhibitor | 0.135 0.099 DBMET01537 | DBMET01537 | |
| 0.057 | 0.554 | 0.251 | RNA-directed DNA polymerase inhibitor | 0.194 0.109 DBMET01535 0.19 0.116 DBMET01536 0.233 0.061 DBMET01537 0.215 0.08 DBMET01538 0.251 0.049 DBMET01539 | DBMET01539 | |
| 0.004 | 0.506 | 0.031 | Retinoic acid receptor agonist | 0.031 0.009 DBMET01535 | DBMET01535 | |
| 0.011 | 0.513 | 0.06 | Dopamine beta hydroxylase inhibitor | 0.06 0.015 DBMET01535 | DBMET01535 | |
| 0.004 | 0.508 | 0.111 | Cholecystokinin A agonist | 0.111 0.004 DBMET01539 | DBMET01539 | |
| 0.004 | 0.509 | 0.02 | Lysophosphatidic acid 1 receptor antagonist | 0.02 0.018 DBMET01535 | DBMET01535 | |
| 0.025 | 0.531 | 0.081 | Granulocyte macrophage colony stimulating factor agonist | 0.081 0.074 DBMET01535 | DBMET01535 | |
| 0.004 | 0.511 | 0.041 | Thymidylate synthase inhibitor | 0.041 0.04 DBMET01535 | DBMET01535 | |
| 0.007 | 0.515 | 0.054 | Sphingosine kinase inhibitor | 0.054 0.053 DBMET01535 | DBMET01535 | |
| 0.023 | 0.531 | 0.124 | Interleukin 8 antagonist | 0.124 0.057 DBMET01537 0.109 0.078 DBMET01538 | DBMET01537 | |
| 0.003 | 0.513 | 0.035 | Lysine carboxypeptidase inhibitor | 0.035 0.012 DBMET01535 | DBMET01535 | |
| 0.029 | 0.542 | 0.408 | Peroxidase inhibitor | 0.147 0.079 DBMET01535 0.128 0.092 DBMET01536 0.408 0.019 DBMET01537 0.289 0.039 DBMET01538 | DBMET01537 | |
| 0.079 | 0.599 | 0.277 | Interleukin 2 agonist | 0.277 0.092 DBMET01535 0.215 0.165 DBMET01537 | DBMET01535 | |
| 0.004 | 0.525 | 0.035 | Neuraminidase (Influenza B) inhibitor | 0.035 0.004 DBMET01535 | DBMET01535 | |
| 0.007 | 0.53 | 0.046 | Lysophosphatidic acid 3 receptor antagonist | 0.046 0.043 DBMET01535 | DBMET01535 | |
| 0.003 | 0.527 | 0.11 | Cholecystokinin agonist | 0.11 0.004 DBMET01539 | DBMET01539 | |
| 0.058 | 0.582 | 0.224 | Sodium/bile acid cotransporter inhibitor | 0.224 0.157 DBMET01535 | DBMET01535 | |
| 0.027 | 0.554 | 0.226 | Antiamyloidogenic | 0.153 0.143 DBMET01537 0.226 0.083 DBMET01538 | DBMET01538 | |
| 0.013 | 0.541 | 0.366 | Anesthetic general | 0.366 0.021 DBMET01535 | DBMET01535 | |
| 0.027 | 0.558 | 0.254 | Succinate dehydrogenase inhibitor | 0.254 0.021 DBMET01535 0.14 0.132 DBMET01537 | DBMET01535 | |
| 0.005 | 0.537 | 0.15 | NMDA receptor antagonist | 0.15 0.024 DBMET01535 | DBMET01535 | |
| 0.034 | 0.567 | 0.308 | Interleukin agonist | 0.308 0.044 DBMET01535 | DBMET01535 | |
| 0.017 | 0.553 | 0.14 | GABA C receptor rho-1 antagonist | 0.14 0.026 DBMET01535 0.106 0.054 DBMET01537 | DBMET01535 | |
| 0.038 | 0.574 | 0.118 | DNA repair enzyme inhibitor | 0.118 0.076 DBMET01535 | DBMET01535 | |
| 0.011 | 0.549 | 0.064 | Potassium channel intermediate-conductance Ca-activated blocker | 0.064 0.035 DBMET01535 | DBMET01535 | |
| 0.016 | 0.556 | 0.12 | AMP-activated protein kinase stimulant | 0.12 0.049 DBMET01535 | DBMET01535 | |
| 0.085 | 0.626 | 0.307 | 5 Hydroxytryptamine uptake stimulant | 0.307 0.041 DBMET01535 | DBMET01535 | |
| 0.019 | 0.563 | 0.106 | Xanthine oxidase inhibitor | 0.106 0.055 DBMET01535 | DBMET01535 | |
| 0.044 | 0.594 | 0.46 | Histamine release inhibitor | 0.46 0.045 DBMET01535 | DBMET01535 | |
| 0.005 | 0.557 | 0.055 | Xanthine dehydrogenase inhibitor | 0.055 0.042 DBMET01535 | DBMET01535 | |
| 0.019 | 0.577 | 0.197 | Angiogenesis stimulant | 0.197 0.096 DBMET01539 | DBMET01539 | |
| 0.009 | 0.574 | 0.073 | NMDA receptor agonist | 0.073 0.034 DBMET01535 | DBMET01535 | |
| 0.004 | 0.575 | 0.058 | Nerve growth factor antagonist | 0.058 0.011 DBMET01535 | DBMET01535 | |
| 0.004 | 0.576 | 0.038 | Nicotinic acid receptor 2 agonist | 0.038 0.022 DBMET01535 | DBMET01535 | |
| 0.01 | 0.586 | 0.073 | Glutamate (mGluR7) antagonist | 0.073 0.038 DBMET01535 | DBMET01535 | |
| 0.011 | 0.592 | 0.079 | Cathepsin G inhibitor | 0.079 0.044 DBMET01535 | DBMET01535 | |
| 0.015 | 0.596 | 0.047 | CD45 antagonist | 0.047 0.042 DBMET01535 | DBMET01535 | |
| 0.02 | 0.601 | 0.123 | Carbonic anhydrase III inhibitor | 0.123 0.042 DBMET01535 | DBMET01535 | |
| 0.03 | 0.614 | 0.216 | Phospholipase C inhibitor | 0.216 0.035 DBMET01535 | DBMET01535 | |
| 0.016 | 0.604 | 0.075 | Carbonic anhydrase VI inhibitor | 0.075 0.064 DBMET01535 | DBMET01535 | |
| 0.021 | 0.609 | 0.204 | NADH dehydrogenase inhibitor | 0.204 0.01 DBMET01535 | DBMET01535 | |
| 0.01 | 0.601 | 0.155 | Mucolytic | 0.155 0.03 DBMET01535 | DBMET01535 | |
| 0.009 | 0.599 | 0.049 | Glutamate (mGluR8) agonist | 0.049 0.012 DBMET01535 | DBMET01535 | |
| 0.015 | 0.612 | 0.145 | Mannose-6-phosphate isomerase inhibitor | 0.145 0.069 DBMET01535 | DBMET01535 | |
| 0.004 | 0.605 | 0.033 | Nicotinic acid receptor agonist | 0.033 0.029 DBMET01535 | DBMET01535 | |
| 0.003 | 0.604 | 0.054 | Carbonic anhydrase VB inhibitor | 0.054 0.041 DBMET01535 | DBMET01535 | |
| 0.012 | 0.615 | 0.389 | Ferrochelatase inhibitor | 0.389 0.004 DBMET01535 | DBMET01535 | |
| 0.009 | 0.615 | 0.123 | GABA aminotransferase inhibitor | 0.123 0.015 DBMET01535 | DBMET01535 | |
| 0.02 | 0.63 | 0.371 | DNA synthesis inhibitor | 0.371 0.026 DBMET01535 | DBMET01535 | |
| 0.001 | 0.615 | 0.016 | Nicotinic acid receptor 1 antagonist | 0.016 0.015 DBMET01535 | DBMET01535 | |
| 0.014 | 0.635 | 0.138 | Anabolic | 0.138 0.025 DBMET01535 | DBMET01535 | |
| 0 | 0.623 | 0.01 | Mannitol 2-dehydrogenase inhibitor | 0.01 0.004 DBMET01535 | DBMET01535 | |
| 0.002 | 0.627 | 0.068 | Guanylate cyclase inhibitor | 0.068 0.005 DBMET01535 | DBMET01535 | |
| 0.005 | 0.631 | 0.038 | Glutamate (mGluR3) agonist | 0.038 0.012 DBMET01535 | DBMET01535 | |
| 0.013 | 0.648 | 0.168 | Arachidonic acid antagonist | 0.168 0.068 DBMET01535 | DBMET01535 | |
| 0.027 | 0.664 | 0.139 | Interferon gamma antagonist | 0.139 0.094 DBMET01535 | DBMET01535 | |
| 0.003 | 0.642 | 0.04 | Vanilloid 2 agonist | 0.04 0.004 DBMET01535 | DBMET01535 | |
| 0.007 | 0.652 | 0.078 | CDC25A inhibitor | 0.078 0.045 DBMET01539 | DBMET01539 | |
| 0.01 | 0.662 | 0.046 | Glutamate (mGluR4) antagonist | 0.046 0.026 DBMET01535 | DBMET01535 | |
| 0.006 | 0.659 | 0.126 | Expectorant | 0.126 0.047 DBMET01535 | DBMET01535 | |
| 0.008 | 0.661 | 0.047 | Glucose-6-phosphate isomerase inhibitor | 0.047 0.034 DBMET01535 | DBMET01535 | |
| 0.054 | 0.707 | 0.241 | Tyrosine 3 hydroxylase inhibitor | 0.241 0.078 DBMET01535 0.198 0.139 DBMET01537 | DBMET01535 | |
| 0.025 | 0.69 | 0.163 | Neurotrophic factor enhancer | 0.163 0.119 DBMET01537 | DBMET01537 | |
| 0.047 | 0.712 | 0.226 | Calcium channel activator | 0.226 0.176 DBMET01535 | DBMET01535 | |
| 0.08 | 0.745 | 0.352 | Calcium channel L-type activator | 0.352 0.116 DBMET01535 0.248 0.207 DBMET01537 | DBMET01535 | |
| 0.003 | 0.669 | 0.033 | RNA-directed RNA polymerase inhibitor | 0.033 0.026 DBMET01535 | DBMET01535 | |
| 0.016 | 0.682 | 0.192 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.192 0.017 DBMET01535 | DBMET01535 | |
| 0.014 | 0.69 | 0.132 | DOPA decarboxylase inhibitor | 0.132 0.033 DBMET01535 0.108 0.061 DBMET01537 | DBMET01535 | |
| 0.008 | 0.684 | 0.054 | Pregnane X receptor antagonist | 0.054 0.047 DBMET01535 | DBMET01535 | |
| 0.013 | 0.69 | 0.148 | Cathepsin H inhibitor | 0.148 0.047 DBMET01535 | DBMET01535 | |
| 0.004 | 0.682 | 0.066 | Catalase inhibitor | 0.066 0.058 DBMET01535 | DBMET01535 | |
| 0.014 | 0.692 | 0.153 | Electrolyte absorption antagonist | 0.153 0.018 DBMET01535 | DBMET01535 | |
| 0.004 | 0.684 | 0.223 | Glutamate decarboxylase inhibitor | 0.223 0.005 DBMET01535 | DBMET01535 | |
| 0.005 | 0.686 | 0.116 | Diuretic | 0.116 0.109 DBMET01535 | DBMET01535 | |
| 0.009 | 0.691 | 0.145 | GABA C receptor antagonist | 0.145 0.033 DBMET01535 0.102 0.075 DBMET01537 | DBMET01535 | |
| 0.033 | 0.722 | 0.255 | Apoptosis agonist | 0.255 0.208 DBMET01538 | DBMET01538 | |
| 0.001 | 0.69 | 0.016 | Carbonic anhydrase X inhibitor | 0.016 0.012 DBMET01535 | DBMET01535 | |
| 0.001 | 0.69 | 0.016 | Carbonic anhydrase VIII inhibitor | 0.016 0.012 DBMET01535 | DBMET01535 | |
| 0.008 | 0.701 | 0.147 | Cholecystokinin B agonist | 0.147 0.005 DBMET01539 | DBMET01539 | |
| 0.018 | 0.712 | 0.234 | Cyclic AMP phosphodiesterase inhibitor | 0.234 0.072 DBMET01535 | DBMET01535 | |
| 0.009 | 0.705 | 0.082 | Uric acid excretion stimulant | 0.082 0.078 DBMET01535 | DBMET01535 | |
| 0.004 | 0.703 | 0.028 | Retinoic acid gamma receptor agonist | 0.028 0.008 DBMET01535 | DBMET01535 | |
| 0.014 | 0.719 | 0.2 | Aldehyde dehydrogenase inhibitor | 0.2 0.028 DBMET01535 | DBMET01535 | |
| 0.002 | 0.707 | 0.05 | Retinoid X alpha receptor agonist | 0.05 0.014 DBMET01535 | DBMET01535 | |
| 0.015 | 0.721 | 0.081 | MAP kinase kinase 7 inhibitor | 0.081 0.043 DBMET01535 | DBMET01535 | |
| 0.007 | 0.715 | 0.045 | Glutamate (mGluR group III) antagonist | 0.045 0.027 DBMET01535 | DBMET01535 | |
| 0.021 | 0.73 | 0.348 | Cholesterol antagonist | 0.348 0.065 DBMET01535 | DBMET01535 | |
| 0.013 | 0.729 | 0.208 | Triose-phosphate isomerase inhibitor | 0.208 0.01 DBMET01535 | DBMET01535 | |
| 0.006 | 0.725 | 0.065 | Adenosine deaminase inhibitor | 0.065 0.016 DBMET01535 | DBMET01535 | |
| 0.004 | 0.725 | 0.029 | Retinoic acid beta receptor agonist | 0.029 0.006 DBMET01535 | DBMET01535 | |
| 0.008 | 0.73 | 0.114 | Ornithine decarboxylase inhibitor | 0.114 0.031 DBMET01535 | DBMET01535 | |
| 0.025 | 0.748 | 0.277 | Vasodilator, coronary | 0.277 0.108 DBMET01535 | DBMET01535 | |
| 0.018 | 0.742 | 0.112 | Photosensitizer | 0.112 0.068 DBMET01535 | DBMET01535 | |
| 0.006 | 0.731 | 0.046 | Kainate receptor agonist | 0.046 0.019 DBMET01535 | DBMET01535 | |
| 0.002 | 0.729 | 0.037 | Retinoid X gamma receptor agonist | 0.037 0.008 DBMET01535 | DBMET01535 | |
| 0.002 | 0.73 | 0.03 | Nicotinic acid receptor 2 antagonist | 0.03 0.013 DBMET01535 | DBMET01535 | |
| 0.016 | 0.746 | 0.423 | Antibacterial | 0.423 0.067 DBMET01535 | DBMET01535 | |
| 0.003 | 0.733 | 0.197 | Acyl-CoA dehydrogenase inhibitor | 0.197 0.005 DBMET01535 | DBMET01535 | |
| 0.01 | 0.741 | 0.081 | Prolactin inhibitor | 0.081 0.079 DBMET01535 | DBMET01535 | |
| 0.023 | 0.755 | 0.272 | Gastrin inhibitor | 0.272 0.055 DBMET01535 | DBMET01535 | |
| 0.009 | 0.741 | 0.212 | UDP-glucose 4-epimerase inhibitor | 0.212 0.017 DBMET01535 | DBMET01535 | |
| 0.002 | 0.737 | 0.035 | Kainate receptor antagonist | 0.035 0.034 DBMET01535 | DBMET01535 | |
| 0.003 | 0.747 | 0.184 | Alcohol oxidase inhibitor | 0.184 0.007 DBMET01535 | DBMET01535 | |
| 0.037 | 0.782 | 0.173 | Ca2+-transporting ATPase inhibitor | 0.173 0.011 DBMET01535 | DBMET01535 | |
| 0.003 | 0.75 | 0.032 | Angiotensin II receptor antagonist | 0.032 0.028 DBMET01535 | DBMET01535 | |
| 0.003 | 0.752 | 0.192 | Argininosuccinate synthase inhibitor | 0.192 0.008 DBMET01535 | DBMET01535 | |
| 0.002 | 0.752 | 0.042 | Angiotensin AT1 receptor antagonist | 0.042 0.029 DBMET01535 | DBMET01535 | |
| 0.001 | 0.752 | 0.049 | Fumarate hydratase inhibitor | 0.049 0.014 DBMET01535 | DBMET01535 | |
| 0.004 | 0.755 | 0.126 | Phenylalanine 4-hydroxylase inhibitor | 0.126 0.016 DBMET01535 | DBMET01535 | |
| 0.003 | 0.758 | 0.041 | Glutamate (mGluR3) antagonist | 0.041 0.02 DBMET01535 | DBMET01535 | |
| 0.006 | 0.762 | 0.04 | AICAR transformylase inhibitor | 0.04 0.038 DBMET01535 | DBMET01535 | |
| 0.004 | 0.763 | 0.16 | Phospholipase A2 inhibitor | 0.16 0.065 DBMET01535 | DBMET01535 | |
| 0.004 | 0.765 | 0.14 | Aconitate hydratase inhibitor | 0.14 0.004 DBMET01535 | DBMET01535 | |
| 0.001 | 0.764 | 0.042 | Retinoid X receptor agonist | 0.042 0.021 DBMET01535 | DBMET01535 | |
| 0.003 | 0.769 | 0.214 | Biliverdin reductase inhibitor | 0.214 0.005 DBMET01535 | DBMET01535 | |
| 0.036 | 0.803 | 0.222 | Lipocortins synthesis antagonist | 0.222 0.044 DBMET01535 | DBMET01535 | |
| 0.003 | 0.771 | 0.061 | Mannosidase inhibitor | 0.061 0.016 DBMET01535 | DBMET01535 | |
| 0.01 | 0.787 | 0.151 | Sphingosine 1-phosphate receptor 5 antagonist | 0.151 0.06 DBMET01535 | DBMET01535 | |
| 0.008 | 0.789 | 0.563 | Alpha-N-acetylglucosaminidase inhibitor | 0.563 0.004 DBMET01535 | DBMET01535 | |
| 0.007 | 0.79 | 0.176 | Immunostimulant | 0.176 0.135 DBMET01535 | DBMET01535 | |
| 0.011 | 0.795 | 0.129 | Adenylate cyclase stimulant | 0.129 0.103 DBMET01535 | DBMET01535 | |
| 0.01 | 0.796 | 0.198 | Aminopeptidase B inhibitor | 0.198 0.022 DBMET01535 | DBMET01535 | |
| 0.018 | 0.806 | 0.247 | Cyclophilin D inhibitor | 0.247 0.216 DBMET01539 | DBMET01539 | |
| 0.001 | 0.791 | 0.022 | Retinoid X beta receptor antagonist | 0.022 0.011 DBMET01535 | DBMET01535 | |
| 0.001 | 0.792 | 0.057 | Arginase inhibitor | 0.057 0.012 DBMET01535 | DBMET01535 | |
| 0.001 | 0.794 | 0.11 | Ornithine carbamoyltransferase inhibitor | 0.11 0.014 DBMET01535 | DBMET01535 | |
| 0.009 | 0.808 | 0.196 | Glutamate dehydrogenase inhibitor | 0.196 0.01 DBMET01535 | DBMET01535 | |
| 0.006 | 0.806 | 0.339 | GABA C receptor agonist | 0.339 0.007 DBMET01535 | DBMET01535 | |
| 0.003 | 0.804 | 0.048 | Membrane dipeptidase inhibitor | 0.048 0.017 DBMET01535 | DBMET01535 | |
| 0.004 | 0.805 | 0.057 | Alpha-mannosidase inhibitor | 0.057 0.031 DBMET01535 | DBMET01535 | |
| 0.017 | 0.822 | 0.253 | Adenylate kinase inhibitor | 0.253 0.01 DBMET01535 | DBMET01535 | |
| 0.006 | 0.814 | 0.155 | Creatine kinase inhibitor | 0.155 0.022 DBMET01535 | DBMET01535 | |
| 0.002 | 0.813 | 0.072 | Carbamoyl phosphate synthetase inhibitor | 0.072 0.033 DBMET01535 | DBMET01535 | |
| 0.003 | 0.817 | 0.22 | Porphobilinogen synthase inhibitor | 0.22 0.01 DBMET01535 | DBMET01535 | |
| 0.015 | 0.83 | 0.271 | Vasodilator, peripheral | 0.271 0.113 DBMET01535 | DBMET01535 | |
| 0.002 | 0.817 | 0.132 | Phosphofructokinase-1 inhibitor | 0.132 0.022 DBMET01535 | DBMET01535 | |
| 0.005 | 0.826 | 0.043 | Retinoid X receptor antagonist | 0.043 0.019 DBMET01535 | DBMET01535 | |
| 0.002 | 0.823 | 0.05 | GABA uptake inhibitor | 0.05 0.015 DBMET01535 | DBMET01535 | |
| 0.007 | 0.83 | 0.069 | Glycine receptor agonist | 0.069 0.057 DBMET01535 | DBMET01535 | |
| 0.005 | 0.828 | 0.039 | Retinoid X alpha receptor antagonist | 0.039 0.017 DBMET01535 | DBMET01535 | |
| 0.002 | 0.839 | 0.02 | Methylmalonyl-CoA mutase inhibitor | 0.02 0.009 DBMET01535 | DBMET01535 | |
| 0.007 | 0.845 | 0.087 | Glutamate (mGluR6) antagonist | 0.087 0.018 DBMET01535 | DBMET01535 | |
| 0.002 | 0.844 | 0.034 | Retinoid X beta receptor agonist | 0.034 0.007 DBMET01535 | DBMET01535 | |
| 0.003 | 0.846 | 0.116 | Alcohol dehydrogenase inhibitor | 0.116 0.038 DBMET01535 | DBMET01535 | |
| 0.003 | 0.854 | 0.03 | Retinoid X gamma receptor antagonist | 0.03 0.013 DBMET01535 | DBMET01535 | |
| 0.003 | 0.871 | 0.106 | Aminopeptidase I inhibitor | 0.106 0.025 DBMET01535 | DBMET01535 | |
| 0.007 | 0.881 | 0.168 | Cell wall synthesis inhibitor | 0.168 0.049 DBMET01535 | DBMET01535 | |
| 0.004 | 0.879 | 0.172 | Protein-tyrosine phosphatase inhibitor | 0.172 0.061 DBMET01539 | DBMET01539 | |
| 0.002 | 0.885 | 0.037 | AMPA 4 receptor antagonist | 0.037 0.032 DBMET01535 | DBMET01535 | |
| 0.008 | 0.898 | 0.035 | Glutamate (mGluR8) antagonist | 0.035 0.027 DBMET01535 | DBMET01535 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |